🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. CAPECITABINE, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Oxaliplatin 5mg/ml concentrate for solution for infusion, CETUXIMAB, ENCORAFENIB, Calcium Folinate 10 mg/ml Injection, CAMPTO 20 mg/mL concentrate for solution for infusion, Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion, CAMPTO 20 mg/mL concentrate for solution for infusion, FLUOROURACIL, IRINOTECAN, Bevacizumab, CALCIUM FOLINATE, Capecitabine, Cetuximab, OXALIPLATIN, Oxaliplatin 5mg/ml concentrate for Solution

    Pfizer Australia Pty Ltd

    Colorectal cancer (BRAF V600E-mutant mCRC)

    phase 3 small molecule active

    1 trial

  2. CAPECITABINE, PACLITAXEL, CAPECITABINE, DS-8201a, Abraxane 5 mg/ml powder for dispersion for infusion.

    AstraZeneca AB

    HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.

    phase 3 small molecule active

    1 trial

  3. CARBOPLATIN , FLUOROURACIL , JNJ-61186372, CISPLATIN , PEMBROLIZUMAB

    Janssen-Cilag International N.V.

    Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  4. CARBOPLATIN, CARBOPLATIN, DS-8201a, PEMETREXED, CISPLATIN, PEMBROLIZUMAB

    Daiichi Sankyo

    Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  5. CARBOPLATIN, CARBOPLATIN, IPILIMUMAB, PEMETREXED, CISPLATIN, INFLIXIMAB, PEMETREXED, Mycofit, 250 mg, kapsułki twarde, NIVOLUMAB, volrustomig

    AstraZeneca AB

    Unresectable Pleural Mesothelioma

    phase 3 small molecule active

    1 trial

  6. CARBOPLATIN, CARBOPLATIN, Patritumab deruxtecan, PEMETREXED, CISPLATIN

    Daiichi Sankyo

    Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  7. CARBOPLATIN, CISPLATIN, PEGFILGRASTIM, PEMETREXED, BL-B01D1

    Bristol-Myers Squibb Australia Pty Ltd

    EGFR-mutated Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  8. CARBOPLATIN, CISPLATIN, PEMBROLIZUMAB, PEMETREXED, DS-8201a, PEMETREXED

    AstraZeneca AB

    Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations

    phase 3 small molecule active

    1 trial

  9. CARBOPLATIN, GEMCITABINE, PEMBROLIZUMAB, CISPLATIN, BT8009, AVELUMAB

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  10. CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride

    Sarepta Therapeutics

    Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.

    phase 3 small molecule active

    1 trial

  11. CBD 100 mg/mL Oral Solution

    COGNITION THERAPEUTICS INC

    Psychosis

    phase 3 small molecule active

    1 trial

  12. CBD 100 mg/mL Oral Solution

    COGNITION THERAPEUTICS INC

    Treatment Resistant Psychosis

    phase 3 small molecule active

    1 trial

  13. CBP-201

    S.L

    Atopic Dermatitis

    phase 3 small molecule active

    2 trials

  14. CDZ173/Leniolisib, CDZ173/Leniolisib

    Pharming Technologies B.V.

    Activated Phosphoinositide 3-Kinase Delta Syndrome

    phase 3 small molecule active

    1 trial

  15. CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib

    Pharming Technologies B.V.

    Activated Phosphoinositide 3-Kinase Delta Syndrome

    phase 3 small molecule active

    1 trial

  16. CEFTAZIDIME, PIPERACILLIN, CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE, CEFTAZIDIME, CEFEPIME , CEFEPIME, MEROPENEM , TAZOBACTAM, TAZOBACTAM, MEROPENEM, AMIKACIN , AMIKACIN, PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE AND BETA-LACTAMASE INHIBITOR , AVIBACTAM, CEFTAZIDIME

    Pari Pharma GmbH

    antibiotic therapy in Sepsis

    phase 3 small molecule active

    1 trial

  17. CEFTRIAXONE , CEFIXIME , SULFAMETHOXAZOLE AND TRIMETHOPRIM , AMIKACIN

    Pari Pharma GmbH

    acute pyelonephritis (AP) in children

    phase 3 small molecule active

    1 trial

  18. CEFTRIAXONE , TEMOCILLIN , Negaban 2 g poudre pour solution injectable/pour perfusion

    Pari Pharma GmbH

    Neisseria gonorrhoeae Infections

    phase 3 small molecule active

    1 trial

  19. CEFTRIAXONE VIATRIS 1 g, poudre pour solution injectable, Clarithromycine EG 500 mg comprimés pelliculés, MÉTRONIDAZOLE ARROW 500 mg, comprimé pelliculé sécable

    Pari Pharma GmbH

    Pregnant women with singleton pregnancies hospitalized for threatened late miscarriage with intact membranes

    phase 3 small molecule active

    1 trial

  20. CEFTRIAXONE, AMOXICILLIN, AZITHROMYCIN

    Pari Pharma GmbH

    Population of study participants Pregnant women with PPROM at 22 to 33 weeks’ gestation

    phase 3 small molecule active

    1 trial

  21. CEP-10953 (Armodafinil)

    Teva Pharma GmbH

    Narcolepsy

    phase 3 small molecule completed

    1 trial

  22. CEP-1347 10mg

    Teva Pharma GmbH

    Parkinson Disease

    phase 3 small molecule terminated

    1 trial

  23. CF101

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  24. CF101

    Can-Fite BioPharma

    Keratoconjunctivitis Sicca

    phase 3 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources